Dose-escalating, Pilot Study to Assess the Safety, Tolerability, and Preliminary Efficacy of ALS-357 Topically Administered to Patients With Cutaneous Metastatic Melanoma
| City: |
|
Chicago |
| State: |
|
Illinois |
| Zip Code: |
|
60611 |
| Conditions: |
|
Melanoma |
| Purpose: |
|
A phase I trial to evaluate the safety and tolerability of ALS-357 when administered for
four weeks as a topical ointment, in escalating doses, to patients with cutaneous metastatic
melanoma and to evaluate the effect of escalating doses of topically applied ALS-357 on
histological remission of cutaneous metastatic melanoma and induction of apoptotic
biomarkers.
|
| Study Summary: |
|
|
| Criteria: |
|
Inclusion Criteria:
- Study Participants must be 18 years or older.
- Study Participants must have 2 sites of cutaneous metastatic melanoma that can not be
removed with surgery.
- Study Participants may have been previously treated with chemotherapy or
immunotherapy but not with in 4 weeks of first dose of study treatment.
|
| NCT ID: |
|
NCT00701987 |
| Primary Contact: |
|
Principal Investigator
Timothy Kuzel, MD
Robert H. Lurie Cancer Center
Timothy Kuzel, MD
Phone: 312-695-1301
|
| Backup Contact: |
|
N/A |
| Location Contact: |
|
Chicago, Illinois 60611
United States
Timothy Kuzel, MD
Phone: 312-695-1301
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 20, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|